{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T07:27:13Z","timestamp":1789457233557,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-025-04477-2","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T10:18:21Z","timestamp":1738750701000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Efficacy of vericiguat in patients with chronic heart failure and reduced ejection fraction: a prospective observational study"],"prefix":"10.1186","volume":"25","author":[{"given":"Yinge","family":"Zhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yishan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuchong","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"issue":"18","key":"4477_CR1","doi-asserted-by":"publisher","first-page":"e876","DOI":"10.1161\/CIR.0000000000001062","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA Guideline for the management of Heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice guidelines. Circulation. 2022;145(18):e876\u201394. https:\/\/doi.org\/10.1161\/CIR.0000000000001062.","journal-title":"Circulation"},{"issue":"12","key":"4477_CR2","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.cardfail.2017.09.014","volume":"23","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Zhang J, Butler J, et al. Contemporary Epidemiology, management, and outcomes of patients hospitalized for heart failure in China: results from the China Heart failure (China-HF) Registry. J Card Fail. 2017;23(12):868\u201375. https:\/\/doi.org\/10.1016\/j.cardfail.2017.09.014.","journal-title":"J Card Fail"},{"issue":"9","key":"4477_CR3","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","volume":"141","author":"SS Virani","year":"2020","unstructured":"Virani SS, Alonso A, Benjamin EJ, et al. Heart Disease and Stroke Statistics-2020 update: a Report from the American Heart Association. Circulation. 2020;141(9):e139\u2013596. https:\/\/doi.org\/10.1161\/CIR.0000000000000757.","journal-title":"Circulation"},{"issue":"4","key":"4477_CR4","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s40256-022-00538-5","volume":"22","author":"C Kang","year":"2022","unstructured":"Kang C, Lamb YN, Vericiguat. A review in Chronic Heart failure with reduced ejection fraction. Am J Cardiovasc Drugs Drugs Devices Interv. 2022;22(4):451\u20139. https:\/\/doi.org\/10.1007\/s40256-022-00538-5.","journal-title":"Am J Cardiovasc Drugs Drugs Devices Interv"},{"issue":"20","key":"4477_CR5","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","volume":"382","author":"PW Armstrong","year":"2020","unstructured":"Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382(20):1883\u201393. https:\/\/doi.org\/10.1056\/NEJMoa1915928.","journal-title":"N Engl J Med"},{"issue":"8","key":"4477_CR6","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1002\/ejhf.2601","volume":"24","author":"M Guazzi","year":"2022","unstructured":"Guazzi M, Wilhelm M, Halle M, et al. Exercise testing in heart failure with preserved ejection fraction: an appraisal through diagnosis, pathophysiology and therapy - A clinical consensus statement of the Heart Failure Association and European Association of Preventive Cardiology of the European Society of Cardiology. Eur J Heart Fail. 2022;24(8):1327\u201345. https:\/\/doi.org\/10.1002\/ejhf.2601.","journal-title":"Eur J Heart Fail"},{"issue":"SupplementD","key":"4477_CR7","doi-asserted-by":"publisher","first-page":"D18","DOI":"10.1093\/eurheartjsupp\/suad111.042","volume":"25","author":"A Olimpieri","year":"2023","unstructured":"Olimpieri A, Ferraro F, Gambardella R, C43 Relationship between echocardiographic data and cardiopulmonary exercise test parameters in adult congenital heart disease patients: a retrospective clinical study. Eur Heart J Suppl. 2023;25(SupplementD):D18\u20139. https:\/\/doi.org\/10.1093\/eurheartjsupp\/suad111.042.","journal-title":"Eur Heart J Suppl"},{"issue":"2","key":"4477_CR8","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.acvdsp.2023.03.023","volume":"15","author":"M Kirsch","year":"2023","unstructured":"Kirsch M, Vitiello D, Traschel LD, et al. Cardiac hemodynamics and individual responses to exercise training in patients with coronary heart disease. Arch Cardiovasc Dis Suppl. 2023;15(2):188\u20139. https:\/\/doi.org\/10.1016\/j.acvdsp.2023.03.023.","journal-title":"Arch Cardiovasc Dis Suppl"},{"key":"4477_CR9","doi-asserted-by":"publisher","unstructured":"Choi J, Park JS, Choi HJ, et al. Peak VO2 and VE\/VCO2 exhibit differential prognostic capacity for predicting cardiac events. Eur Heart J. 2023;44(Supplement2): ehad655.931. https:\/\/doi.org\/10.1093\/eurheartj\/ehad655.931","DOI":"10.1093\/eurheartj\/ehad655.931"},{"issue":"6 Pt 2","key":"4477_CR10","first-page":"VI40","volume":"76","author":"KT Weber","year":"1987","unstructured":"Weber KT, Janicki JS, McElroy PA. Determination of aerobic capacity and the severity of chronic cardiac and circulatory failure. Circulation. 1987;76(6 Pt 2):VI40\u201345.","journal-title":"Circulation"},{"issue":"5","key":"4477_CR11","doi-asserted-by":"publisher","first-page":"e018822","DOI":"10.1161\/JAHA.120.018822","volume":"10","author":"M Guazzi","year":"2021","unstructured":"Guazzi M, Borlaug B, Metra M, et al. Revisiting and implementing the Weber and Ventilatory Functional classifications in Heart failure by cardiopulmonary imaging phenotyping. J Am Heart Assoc. 2021;10(5):e018822. https:\/\/doi.org\/10.1161\/JAHA.120.018822.","journal-title":"J Am Heart Assoc"},{"issue":"22","key":"4477_CR12","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1016\/j.jacc.2021.07.052","volume":"78","author":"M Writing Committee Members, Gulati","year":"2021","unstructured":"Writing Committee Members, Gulati M, Levy PD, et al. 2021 AHA\/ACC\/ASE\/CHEST\/SAEM\/SCCT\/SCMR Guideline for the evaluation and diagnosis of chest Pain: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice guidelines. J Am Coll Cardiol. 2021;78(22):2218\u201361. https:\/\/doi.org\/10.1016\/j.jacc.2021.07.052.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"4477_CR13","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.nurpra.2021.07.010","volume":"17","author":"D Harrington","year":"2021","unstructured":"Harrington D, Lenahan CM. Vericiguat\u2014A New Addition for Heart failure with reduced ejection fraction. J Nurse Pract. 2021;17(9):1151\u20133. https:\/\/doi.org\/10.1016\/j.nurpra.2021.07.010.","journal-title":"J Nurse Pract"},{"issue":"12","key":"4477_CR14","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1111\/cts.13677","volume":"16","author":"ME Trujillo","year":"2023","unstructured":"Trujillo ME, Ayalasomayajula S, Blaustein RO, Gheyas F. Vericiguat, a novel sGC stimulator: mechanism of action, clinical, and translational science. Clin Transl Sci. 2023;16(12):2458\u201366. https:\/\/doi.org\/10.1111\/cts.13677.","journal-title":"Clin Transl Sci"},{"issue":"6","key":"4477_CR15","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1161\/CIRCHEARTFAILURE.113.000575","volume":"6","author":"Q Kong","year":"2013","unstructured":"Kong Q, Blanton RM. Protein kinase G I and heart failure: shifting focus from vascular unloading to direct myocardial antiremodeling effects. Circ Heart Fail. 2013;6(6):1268\u201383. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.113.000575.","journal-title":"Circ Heart Fail"},{"issue":"6","key":"4477_CR16","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1007\/s10741-022-10239-5","volume":"27","author":"F Triposkiadis","year":"2022","unstructured":"Triposkiadis F, Xanthopoulos A, Skoularigis J, Starling RC. Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure. Heart Fail Rev. 2022;27(6):1991\u20132003. https:\/\/doi.org\/10.1007\/s10741-022-10239-5.","journal-title":"Heart Fail Rev"},{"issue":"5","key":"4477_CR17","doi-asserted-by":"publisher","first-page":"101586","DOI":"10.1016\/j.cpcardiol.2023.101586","volume":"48","author":"TG Shaikh","year":"2023","unstructured":"Shaikh TG, Jawed S, Rahmat ZS, et al. Efficacy and safety of Vericiguat for Treatment of Heart failure: a systematic review. Curr Probl Cardiol. 2023;48(5):101586. https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.101586.","journal-title":"Curr Probl Cardiol"},{"issue":"1","key":"4477_CR18","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s42003-022-03140-2","volume":"5","author":"S Hildebrand","year":"2022","unstructured":"Hildebrand S, Ibrahim M, Schlitzer A, Maegdefessel L, R\u00f6ll W, Pfeifer A. PDGF regulates guanylate cyclase expression and cGMP signaling in vascular smooth muscle. Commun Biol. 2022;5(1):197. https:\/\/doi.org\/10.1038\/s42003-022-03140-2.","journal-title":"Commun Biol"},{"issue":"11","key":"4477_CR19","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.jacc.2020.01.014","volume":"75","author":"SP Murphy","year":"2020","unstructured":"Murphy SP, Kakkar R, McCarthy CP, Januzzi JL. Inflammation in Heart failure: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(11):1324\u201340. https:\/\/doi.org\/10.1016\/j.jacc.2020.01.014.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"4477_CR20","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jchf.2017.08.013","volume":"6","author":"PW Armstrong","year":"2018","unstructured":"Armstrong PW, Roessig L, Patel MJ, et al. A Multicenter, Randomized, Double-Blind, placebo-controlled trial of the efficacy and safety of the oral Soluble Guanylate Cyclase Stimulator: the VICTORIA Trial. JACC Heart Fail. 2018;6(2):96\u2013104. https:\/\/doi.org\/10.1016\/j.jchf.2017.08.013.","journal-title":"JACC Heart Fail"},{"issue":"12","key":"4477_CR21","doi-asserted-by":"publisher","first-page":"5146","DOI":"10.1021\/acs.jmedchem.7b00449","volume":"60","author":"M Follmann","year":"2017","unstructured":"Follmann M, Ackerstaff J, Redlich G, et al. Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the treatment of Chronic Heart failure. J Med Chem. 2017;60(12):5146\u201361. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b00449.","journal-title":"J Med Chem"},{"issue":"18","key":"4477_CR22","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA Guideline for the management of Heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice guidelines. Circulation. 2022;145(18):e895\u20131032. https:\/\/doi.org\/10.1161\/CIR.0000000000001063.","journal-title":"Circulation"},{"key":"4477_CR23","doi-asserted-by":"publisher","first-page":"971108","DOI":"10.3389\/fcvm.2022.971108","volume":"9","author":"M Mapelli","year":"2022","unstructured":"Mapelli M, Mattavelli I, Salvioni E, et al. Impact of Sacubitril\/Valsartan on surfactant binding proteins, central sleep apneas, lung function tests and heart failure biomarkers: hemodynamic or pleiotropism? Front Cardiovasc Med. 2022;9:971108. https:\/\/doi.org\/10.3389\/fcvm.2022.971108.","journal-title":"Front Cardiovasc Med"},{"issue":"6","key":"4477_CR24","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s10741-023-10337-y","volume":"28","author":"CA Brawner","year":"2023","unstructured":"Brawner CA, Lazar MH. Cardiopulmonary exercise testing criteria for advanced therapies in patients with heart failure. Heart Fail Rev. 2023;28(6):1297\u2013306. https:\/\/doi.org\/10.1007\/s10741-023-10337-y.","journal-title":"Heart Fail Rev"},{"issue":"11","key":"4477_CR25","doi-asserted-by":"publisher","first-page":"e20230077","DOI":"10.36660\/abc.20230077","volume":"120","author":"PH Engster","year":"2023","unstructured":"Engster PH, de Zimerman B, Schaan A. Incremental role of New York Heart Association Class and Cardiopulmonary Exercise Test indices for Prognostication in Heart failure: a Cohort Study. Arq Bras Cardiol. 2023;120(11):e20230077. https:\/\/doi.org\/10.36660\/abc.20230077.","journal-title":"Arq Bras Cardiol"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-04477-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-025-04477-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-04477-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T10:18:24Z","timestamp":1738750704000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-025-04477-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,5]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4477"],"URL":"https:\/\/doi.org\/10.1186\/s12872-025-04477-2","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,5]]},"assertion":[{"value":"7 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Ethics Committee of The First Hospital of Hebei Medical University, and the study was performed in accordance with the Helsinki II declaration. Informed consent was obtained from all the study subjects before enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The use of vericiguat in HFrEF patients is safe and can improve their heart function and exercise tolerance.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"83"}}